A drug interaction between troglitazone and simvastatin

被引：12

作者：

Lin, JC

Ito, MK

机构：

[1] Vet Affairs San Diego Healthcare Syst, Cardiovasc Pharmacodynam Lab, San Diego, CA 92161 USA

[2] Univ Pacific, Sch Pharm & Hlth Sci, Stockton, CA 95211 USA

来源：

DIABETES CARE | 1999年 / 22卷 / 12期

关键词：

D O I：

10.2337/diacare.22.12.2104a

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2104 / 2105

页数：2

共 10 条

[1] Drug interactions of lipid-altering drugs [J].

Bays, HE ;

Dujovne, CA .

DRUG SAFETY, 1998, 19 (05) :355-371

[2]

DAUBRESSE JC, 1993, AM J CARDIOL, V71, P1408

[3] Rationale, design, and baseline results of the pravastatin-to-simvastatin conversion lipid optimization program (PSCOP) [J].

Ito, MK ;

Stolley, SN ;

Morreale, AP ;

Lin, JC ;

Marcus, DB .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (11) :1107-1113

[4]

ITO MK, 1999, PHARMACOTHERAPY, V19, P510

[5] TROGLITAZONE PREVENTS GLUCOSE-INDUCED INSULIN-RESISTANCE OF INSULIN-RECEPTOR IN RAT-1 FIBROBLASTS [J].

KELLERER, M ;

KRODER, G ;

TIPPMER, S ;

BERTI, L ;

KIEHN, R ;

MOSTHAF, L ;

HARING, H .

DIABETES, 1994, 43 (03) :447-453

[6]

LORI CM, 1998, CLIN PHARMACOL THER, V63, P228

[7]

PARKEDAVIS, 1997, RESULIN TROGLITAZONE

[8] Thiazolidinediones in the treatment of insulin resistance and type II diabetes [J].

Saltiel, AR ;

Olefsky, JM .

DIABETES, 1996, 45 (12) :1661-1669

[9] In vitro comparative inhibition profiles of major human drug metabolising cytochrome p450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors [J].

Transon, C ;

Leemann, T ;

Dayer, P .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (03) :209-215

[10]

WHITCOMB RW, 1995, EXPERT OPIN INV DRUG, V4, P1299

← 1 →